/

Società

D&

Non verificato

D&D Pharmatech, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

6 comunicati stampa

Guarda tutti i comunicati

21/07/2026

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

D&D Pharmatech Announces The Lancet Gastroenterology & Hepatology Publication of Phase 2 Data Demonstrating Rapid, Weight-Independent Activity of Zabopegdutide (DD01) in MASLD/MASH

Fonte

D&D Pharmatech, Inc.

Emittente

1.00

0

27/05/2026

Industria

Salute

Scienza

Medicina - Varie

Farmaceutica

Biotecnologia

D&D Pharmatech Announces Positive 48-Week Histology Results for Zabopegdutide (DD01), Demonstrating Statistically Significant Fibrosis Improvement and MASH Resolution

Fonte

D&D Pharmatech, Inc.

Emittente

1.00

0

16/06/2025

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Industria

D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health

Fonte

D&D Pharmatech, Inc.

Emittente

1.00

0

03/02/2025

Salute

Igiene alimentare

Medicina - Varie

Farmaceutica

Biotecnologia

Industria

D&D Pharmatech Announces Completion of Patient Enrollment for a 48-Week Phase 2 Trial Evaluating the Effectiveness of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist, in the Treatment of MASH

Fonte

D&D Pharmatech, Inc.

Emittente

1.00

0

21/08/2024

Igiene alimentare

Salute

Medicina - Varie

Farmaceutica

Biotecnologia

D&D Pharmatech Announces Initiation of Dosing in a Phase 2 Trial Designed to Evaluate the Efficacy and Safety of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist in Overweight/Obese Subjects with MASLD/MASH

Fonte

D&D Pharmatech, Inc.

Emittente

1.00

0

02/04/2024

Accessori

Vetrine/Shopping

Medicina - Varie

D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH

Fonte

D&D Pharmatech, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0